newsfilter
← Latest News
GlobeNewswire·

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

  • CytomX Therapeutics received FDA Fast Track designation for Varsetatug masetecan (Varseta-M) for relapsed/refractory metastatic colorectal cancer.
  • Phase 1 monotherapy data update in metastatic colorectal cancer is expected in January 2027.
  • A Phase 1 study of Varseta-M in combination with bevacizumab for 3L+ mCRC is ongoing.
  • A Phase 1/2 chemotherapy combination study for 2L mCRC is expected to initiate by year-end 2026.
  • Phase 1 expansion cohorts for Varseta-M monotherapy are in progress for gastric/GEJ cancer, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer.
  • CytomX's second candidate, CX-801, continues Phase 1 enrollment in advanced melanoma, having reached the fourth dose level for monotherapy.
  • Phase 1 dose escalation for CX-801 in combination with KEYTRUDA in advanced melanoma has cleared the third dose level.
  • Initial clinical data for CX-801 in combination with KEYTRUDA is expected in the first half of 2027.
  • CytomX held $348.0 million in cash, cash equivalents, and investments at the end of Q3 2026, with a runway into the second half of 2028.
  • Total revenue for Q3 2026 was $1.7 million, a decrease from $6.0 million in Q3 2025 driven by the completion of the Astellas collaboration.
  • Total operating expenses for Q3 2026 increased to $25.2 million from $21.7 million in Q3 2025.
  • Research and development expenses rose to $16.5 million in Q3 2026 due to increased personnel costs, partially offset by lower Varseta-M manufacturing spend.
  • General and administrative expenses increased to $8.7 million in Q3 2026 due to personnel, consulting, and rent expenses associated with moving to a new Emeryville headquarters.
  • CytomX plans to host a conference call today at 5 p.m. ET / 2 p.m. PT to discuss Q3 2026 financial results.
Company
CytomX Therapeutics Inc.
Keywords
Nasdaq:CTMX, CytomX Therapeutics Inc.